A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
Explore this paper's citation graph
Summary
As compared with bare-metal stents, the slow-release, polymer-based, paclitaxel-eluting stent is safe and markedly reduces the rates of clinical and angiographic restenosis at nine months.
- Type
- article
- Published
- 2004-01-15
- Cited by
- 2,869
- References
- 29
- Access
- Open access
- OpenAlex
- https://openalex.org/W1989556574
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:70531312
Keywords
Medicine, Restenosis, Stent, Neointimal hyperplasia, Stenosis
References
- Effects of taxol on human neutrophils.
- Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era.
- A new approach for the quantification of complex lesion morphology: the gradient field transform; basic principles and validation results.
- Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery.
- Inhibition of smooth muscle cell proliferation after local drug delivery of the antimitotic drug paclitaxel using a porous balloon catheter
- Calcium pyrophosphate dihydrate crystals activate MAP kinase in human neutrophils: inhibition of MAP kinase, oxidase activation and degranulation responses of neutrophils by taxol
- A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.
- Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome.
- Predictive factors of restenosis after coronary stent placement.
- Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat.
- Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
- Complete inhibition of intimal hyperplasia by perivascular delivery of paclitaxel in balloon-injured rat carotid arteries.
- Pathology of acute and chronic coronary stenting in humans.
- Inhibition of activator protein 1 activity by paclitaxel suppresses interleukin-1-induced collagenase and stromelysin expression by bovine chondrocytes.
- A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
- Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
- Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo.
- Acute and long-term cost implications of coronary stenting.
- TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions
- Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions
Cited by
- Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials.
- Fourth annual American College of Cardiology international lecture: a journey in the interventional field.
- Coronary artery bypass grafting in DES era.
- Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial.
- Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial.
- Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplas
- Looking for the culprit of coronary in‐stent restenosis: debatable role for the fibrinolytic system?
- Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
- Treatment of unprotected left main coronary artery disease with drug-eluting stents: is it time for a randomized trial?
- Comparative endoluminal visualization of TAXUS crush-stenting at 9 months follow-up by intravascular ultrasound and optical coherence tomography
- Drug/device combinations for local drug therapies and infection prophylaxis.
- Is there an alternative to systemic anticoagulation, as related to interventional biomedical devices?
- Coronary interventional devices: balloon, atherectomy, thrombectomy and distal protection devices.
- Use of drug-eluting stents in Victorian public hospitals.
- Drug-eluting stents versus coronary artery bypass grafting in patients with diabetes mellitus.
- Unstable angina patients treated with percutaneous coronary intervention in the new millennium: what characterizes them?
- Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
- Improved endothelial cell adhesion and proliferation on patterned titanium surfaces with rationally designed, micrometer to nanometer features.
- Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials.
- Variable histological and ultrasonic characteristics of restenosis after drug-eluting stents.
Related papers
- Short- and long-term effects of a novel paclitaxel coated stent in the porcine coronary model
- Safety and efficacy of a novel iopromide-based paclitaxel-eluting balloon following bare metal stent implantation in rabbit aorta abdominalis
- The Paclitaxel-Eluting Stent in Percutaneous Coronary Intervention: Part I: Background and Clinical Comparison to Bare Metal Stents
- The Control of Drug Release and Vascular Endothelialization after Hyaluronic Acid-Coated Paclitaxel Multi-Layer Coating Stent Implantation in Porcine Coronary Restenosis Model
- Intravascular imaging analysis of a drug-eluting balloon followed by a bare metal stent compared to a drug-eluting stent for treatment of de novo lesions
- Impact of stent length on restenosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: analysis based on data from the Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON)
- Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study.
- Effects of stent length and lesion length on coronary restenosis.